BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

  Exelixis, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance for full year 2023, and delivered an update on its business.

  January 8, 2023

   · 

  21 min read
• Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference

  Ascendis Pharma A/S provided an update on its Vision 3x3 strategic roadmap and planned 2023 key corporate milestones.

  January 8, 2023

   · 

  8 min read
• Business

  Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

  Telix Pharmaceuticals Limited advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

  January 8, 2023

   · 

  4 min read
• Business

  Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

  Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.

  January 8, 2023

   · 

  9 min read
• Business

  Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022.

  January 8, 2023

   · 

  8 min read
• Drug Development

  Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

  Genexine announced updated results following the completion of its Phase 2 clinical study using GX-188E, its first-in-class proprietary DNA vaccine, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy.

  January 8, 2023

   · 

  5 min read